Synaptogenix Inc (SNPX)

[F1ash]

I have tried, unsuccessfully for the most part. Unfortunately, often having money at stake removes all objectivity. Anyone who points out inconsistencies or ridiculous statements like "Our unblinded, non-placebo controlled, underpowered, two year long dose optimization study was designed to fail quickly" is just trying to "steal shares" apparently.

The most egregious sin imho is the fact that they are presenting charts labeled "all patients" for a time period that covers a trial that started with 32 patient's and ended with 25. If "all patients means 32 then they somehow "filled in" the missing data for the dropouts. They should declare what method they used.

If they mean 25 when saying "all patients", that is very very misleading. IR ignored my request for clarification. Disconcerting!!!